[Impact of bone metastasis on the prognosis of lung adenocarcinoma patients treated with third-generation EGFR-TKI and the underlying mechanisms].

PubMed 2026

View at publisher
Authors: C Zhang, X L Shi, Y Q Jiang, J Li, J L Xu, R H Guo
DOI: 10.3760/cma.j.cn112137-20251110-02936
Cited by: 0

Abstract

Bone metastasis is an adverse prognostic factor for progression-free survival in lung adenocarcinoma patients treated with third-generation EGFR-TKI. Bone metastasis lesions exhibit a distinct immunosuppressive tumor microenvironment in EGFR-mutant advanced lung adenocarcinoma, in which upregulation of immune regulatory genes in cancer cells and dysfunction of immune cells may constitute a potential mechanism underlying resistance to third-generation EGFR-TKI.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Metastasis and carcinoma case studies Lung Cancer Research Studies

Publication details

Journal / source
PubMed
Volume
106
Issue
22
Pages
2233–2242
Publication date
16 June 2026
Language
ZH